PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV

Wegovy Rebound? STEP 4 Semaglutide Weight Loss Trial Results

9:23Dec 2021

Today’s cheapest Wegovy$208/mo at Sesame Care, an average: a $59/mo subscription billed $708 once a year, with medication billed monthly.Compare all Wegovy prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. Not from the video’s creator.

Our summary

The speaker, who says he is the founder of fit for freelance and a health coach, medical scientist and medical writer, walks through the STEP 4 trial of semaglutide (Wegovy). He says it was published in April 2021, and he notes he is not a doctor. He explains the trial design: 803 participants first completed a 20-week run-in on weekly treatment, with a mean weight loss of 10.6 percent of body weight. They were then randomized for 48 weeks to either keep taking semaglutide or switch to placebo. He says everyone received a lifestyle program for the full 68 weeks, with 150 minutes of physical activity per week and a diet 500 calories per day below needs.

Published by fitforfreelance on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

The speaker describes the charts. According to him, people who switched to placebo regained waist circumference (he says about two inches) and body weight, while those who continued semaglutide kept losing. He says over 80 percent of the continued-treatment group lost 5 percent or more of body weight, and about 40 percent lost 20 percent or more (he says "pounds" in the captions). From week 20 to week 68, he reports a change of minus 7.9 percent in the treatment group, versus a 6.9 percent weight regain in the placebo group, and he calls the difference statistically significant. He reads this as a sign that weight may return after stopping, and that people may need to continue based on their doctor's advice. He also says almost half of those treated for 68 weeks had stomach-related side effects such as nausea.

The last part is more personal commentary. The speaker says habit and behavior changes matter whether or not someone uses the injections, and that even temporary weight loss is better than continued weight gain. He also promotes his coaching and a free checklist, and asks viewers whether they would use weekly injections for weight loss.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 1:02 The speaker says STEP 4 had 803 participants who finished a 20-week run-in with a mean weight loss of 10.6 percent, then were randomized to semaglutide or placebo for 48 weeks.
  2. 1:33 He says everyone also followed a lifestyle program for 68 weeks, including 150 minutes of weekly physical activity and a 500 calorie per day deficit diet.
  3. 3:33 According to the speaker, waist circumference and body weight rose again after switching to placebo, while continued semaglutide led to further loss.
  4. 4:39 He reports that over 80 percent of the continued-treatment group lost 5 percent or more of body weight, and about 40 percent lost 20 percent or more.
  5. 6:11 He says weight change from week 20 to 68 was minus 7.9 percent with treatment and a 6.9 percent regain after stopping, a statistically significant difference.
  6. 6:43 The speaker says almost half of participants treated for 68 weeks had stomach-related side effects, and he advises talking to a healthcare provider.

Key moments

Tap one to play from there.

  1. 0:00 Intro
  2. 1:15 Method
  3. 3:24 Results

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Wegovy and semaglutide

Questions this video answers

Do you regain weight after stopping Wegovy?

According to the speaker, participants in the STEP 4 trial who switched to placebo after 20 weeks regained about 6.9 percent of their weight, while those who continued semaglutide kept losing. He says this suggests people may need to continue treatment, based on their doctor's recommendations.

How was the STEP 4 semaglutide trial designed?

The speaker says 803 participants completed a 20-week run-in on weekly semaglutide, titrated up to 2.4 milligrams. They were then randomized for 48 weeks to continue semaglutide or take placebo, with a lifestyle program of 150 minutes of physical activity per week and a 500 calorie per day deficit throughout.

What side effects were reported in the STEP 4 trial?

The speaker says almost half of the participants who received 68 weeks of treatment had stomach-related side effects, such as nausea and stomach upset. He also says the drug affects appetite.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • Saxenda vs Wegovy: weight loss results, cost and what changes in 2027

    Wegovy beat Saxenda in the only head-to-head trial: 15.8% average weight loss on weekly semaglutide against 6.4% on daily liraglutide over 68 weeks. Wegovy is one injection a week, Saxenda one a day. A pharmacy pays almost the same for 30 days of each, and Novo Nordisk is discontinuing Saxenda in the US, with last shipments in late January 2027. Here is the full comparison, the labels side by side, and what Wegovy costs on the programs we track today.

  • Stopping a GLP-1: what the withdrawal trials found, and what a maintenance dose actually is

    Two trials have measured what happens when you stop. On semaglutide, people who lost 17.3% over 68 weeks regained two-thirds of it in the year after stopping, ending 5.6% below where they started. On tirzepatide, people who lost 20.9% in 36 weeks regained 14% over the next year on placebo while those who continued lost a further 5.5%. Both labels are explicit that these drugs are for maintaining weight reduction long term, which is a different claim from finishing a course. A maintenance dose is simply the dose you stay on; the labels do not define a lower one to step down to at goal.

  • Semaglutide for weight loss: which version, and what each costs

    Semaglutide is the molecule. For weight loss the FDA-approved version is Wegovy, sold as a weekly pen and a daily tablet. Ozempic is the same molecule approved for type 2 diabetes, so using it for weight is off-label. Compounded semaglutide uses semaglutide as its active ingredient, comes from a compounding pharmacy, is not FDA-approved, and is what most cash buyers actually take because it costs a fraction of the brand. All three produce the same side effects. What differs is the approval, the oversight and the price.

Next steps

Wegovy prices

Insurance

Find more like it

Side effectsDose changeWeigh-in and resultsStopping and maintenanceThe trials

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV